4 Analysts Have This to Say About bluebird bio
Portfolio Pulse from Benzinga Insights
bluebird bio (NASDAQ:BLUE) has received mixed analyst ratings in the last quarter, with 1 bullish, 2 somewhat bullish, and 1 indifferent rating. The average 12-month price target among 4 analysts is $9.75, with a high of $13.00 and a low of $7.00. This target has increased by 14.71% from the previous average of $8.50. Analysts rate stocks based on financial statements, meetings, and insider information, providing guidance through their ratings.
December 12, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
bluebird bio has a new average analyst price target of $9.75, reflecting a positive sentiment with an increase from the previous target of $8.50. The ratings are mixed but lean towards a positive outlook with most analysts being bullish or somewhat bullish.
The increase in the average price target suggests a positive sentiment towards BLUE's stock. The predominance of bullish and somewhat bullish ratings indicates that analysts see potential in the company, which could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100